



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

SKLAR ET AL.

SERIAL NUMBER: 09/370,358

FILED: AUGUST 9, 1999

FOR: DISPLAY OF RECEPTORS AND ANALYSIS OF  
BINDING INTERACTIONS AND DRUG LIBRARIES

**RECEIVED**

NOV 30 2001

TECH CENTER 1600/2900

) Art Unit: 1646

) Examiner: BRANNOCK, M.

) DOCKET NO: UNME-0078-1

Director of the U.S. Patent and Trademark Office  
Washington, D.C. 20231

**LETTER**


Sir:

The below-identified communication(s) is (are) submitted in the above-captioned application or proceeding:

☒ Amendment

☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication, including fees under 37 C.F.R. §§ 1.16 and 1.17 or credit any overpayment to **Deposit Account Number 10-0233, UNME-0078-1.**

Respectfully submitted,

  
Mark J. Guttag  
Registration Number 33,057

November 28, 2001

**JAGTIANI + GUTTAG**  
Democracy Square Business Center  
10379-B Democracy Lane  
Fairfax, Virginia 22030

(703) 591-2664

#21/C  
MB  
12/04/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



RECEIVED

NOV 30 2001

In re Application of:

SKLAR ET AL.

SERIAL NUMBER: 09/370,358

FILED: AUGUST 9, 1999

FOR: DISPLAY OF RECEPTORS AND ANALYSIS OF  
BINDING INTERACTIONS AND DRUG LIBRARIES

TECH CENTER 1600/2900

) Art Unit: 1646

) Examiner: BRANNOCK, M.

) DOCKET NO: UNME-0078-1

Director of the U.S. Patent and Trademark Office  
Washington, D.C. 20231

AMENDMENT

Sir:

This is in response to the Office Action mailed on August 28, 2001, the period of response to which is set to expire on November 28, 2001. Please amend the above-captioned application, without prejudice or disclaimer, as follows:

IN THE CLAIMS

Please amend the following claims, without prejudice or disclaimer, as indicated in the accompanying Appendix A: Amendment in Redline Form, and as indicated below in clean form:

Please cancel claim 7 without prejudice or disclaimer.

1. (Amended) A method for non-cellular display of 7-transmembrane receptors comprising the following steps:
- incorporating an attachment tether to a receptor;
  - solubilizing the receptor; and
  - presenting the receptor in conjunction with a support, wherein said support comprises at least one substrate selected from the group consisting of silica bead substrates, latex bead substrates and other bead substrates appropriate for flow cytometry, and wherein the receptor in conjunction with a support is analyzed with a flow cytometer.